US FDA Office Of New Drugs Has New Deputy Director In Thanh Hai
Executive Summary
The move means Hylton Joffe can focus exclusively on his role as director of the Office of Rare Diseases.
You may also be interested in...
US FDA Drug Office Reorg Enters Homestretch With Leadership Nods For Three Clinical Offices
Hylton Joffe was named acting director of the new Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine but also will continue to serve as Office of New Drugs acting deputy director; agency veterans Ellis Unger and Julie Beitz also tapped for clinical office leadership roles in final stage of massive reorg.
US FDA Office Of New Drugs Reorg: Phase 3 Pushed To January
The FDA has confirmed the picks to head most of the new offices in the restructured drug review organization, with one notable exception. The choice for the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine is still pending, while one candidate – Hylton Joffe – will be serving as acting OND deputy director.
US FDA's Acting Orphan Products Development Director Has Gene Therapy Background
Ilan Irony will take over as acting director of the Office of Orphan Products Development later this month.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: